iBio Inc (IBIO)

[maxxm]

IBIO patents and technologies are part of the emergency response to Ebola.
The transaction with Aspire Capital is highly favorable to existing shareholders.
IBIO is progressing rapidly on opportunities much larger than Ebola products.

The successful winner or winners of the new BARDA contract, after proposals are submitted by November 10, will require a license from iBio and will have to form a contractual arrangement with a manufacturing company capable of rapid, large scale production of recombinant proteins in plants such as iBio's collaborator, Caliber Biotherapeutics. Scientific data published by Mapp has demonstrated superior efficacy of plant-made versus CHO-made antibodies, so it's clear why BARDA wants to scale up the product using the same methods that were used to produce it for the highly successful monkey studies, also published in scientific journals showing 100% survival for ZMapp-treated monkeys and 100% mortality for untreated controls.
http://seekingalpha.com/article/2578145-ibios-role-in-ebola-response-illustrates-the-companys-strength